Short answer
Rezolute, Inc. (RZLT) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$18M
- −18.0% YoY
- EPS (diluted)
- −$0.18
- +18.2% YoY
Source: XBRL data from the Rezolute, Inc. (RZLT) Q3 2025 10-Q on SEC EDGAR. USD.
Rezolute, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0 for Q3 2025, unchanged from $0 in Q3 2024
- R&D expenses $13.1M, up 3% YoY from $12.8M
- G&A expenses $6.7M, up 59% YoY from $4.2M
- Best-performing program sunRIZE congenital HI study, enrollment completed May 2025
- Cash and short-term securities $152.2M at September 30, 2025, supporting at least 12 months of operations
Risk Factors
- No risk-factors section provided in the excerpt
- No newly added, updated, regulatory, operational, competitive, market, or financial risks identifiable
- Filing excerpt limited to Items 2–6 and exhibits
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Rezolute, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.